An interventional study of predictive value of a blood test in Dementia Alzheimers, sponsored by Helse Stavanger HF. Recruiting at 1 site in Norway. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Helse Stavanger HF · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Alzheimer Disease with a site in Norway — 11 open to participants now, 15 under way, none of them phase 3. Alzheimer Disease · Norway.
Among the 43 studies in Alzheimer Disease with a site in Norway, this one is the 11th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2023, is one of 18 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 30th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →11 of the 43 studies in Alzheimer Disease with a site in Norway are open now. Recruiting first, the newest first:
Haukeland University Hospital · Sites in Norway
Ages 50–85
University Hospital of North Norway · Sites in Norway
Ages 18+
Diakonhjemmet Hospital · Sites in Norway
Ages 50+
GlaxoSmithKline · Sites in Norway, United States, Argentina and 8 more countries
Ages 50–85
NORCE Norwegian Research Centre AS · Sites in Norway, Argentina, Austria
Ages 65+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 40 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 187 across the 37 interventional studies, 215 across the 6 observational. Of the 25 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 43 have an industry lead sponsor. The 10 most frequent:
Helse Stavanger HF is the lead sponsor of 97 studies on the registry; 18 are open to participants now.
Helse Stavanger HF has 5 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Alzheimer Disease with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05187819Helse Stavanger HFBlood-based Biomarkers for Diagnosis of Alzheimer's | 2026-12-31 |
| NCT05068830Norwegian University of Science and TechnologySafety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease | 2027-03-01 |
| NCT06611878NORCE Norwegian Research Centre ASMemory for Music: Individual Intensive Musical Training in Alzheimer's Disease | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Alzheimer Disease with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD.
This project will assess the predictive value of these tests in a general practice population.
The hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.
A correct diagnosis of dementia is important in order to provide the patient and relatives with right information, and to give adequate treatment and support, but also to improve research and further development of treatment. Alzheimer's disease (AD) is the cause of nearly 2/3 of cases of dementia. Current diagnostic methods to ensure accurate diagnosis include analysis of cerebrospinal fluid and molecular PET, but these methods are expensive and not widely available.
Progress has been made in the development of blood-based diagnostic biomarkers for Alzheimer's disease. It will lead to significant simplification and improvement of clinical practice if simple blood tests that can be taken in general practice can provide a reliable diagnosis of Alzheimer's disease.
Several biomarkers (including phosphorylated tau 181, phosphorylated tau 217, phosphorylated tau 231, plasma glial fibrillary acidic protein, plasma β-amyloid 42 to β-amyloid 40 ratio, and plasma neurofilament light) has documented to be useful to distinguish Alzheimer's dementia from non-Alzheimer's dementia in research cohorts with a high prevalence of AD. This project aims to analyze the diagnostic ability of such biomarkers in a primary care cohort with a lower prevalence of AD.
The Stavanger region in Norway will be the catchment area for recruitment of study participants. The region is geographically distinct with 373,000 inhabitants, 15 municipalities with 320 GPs in 94 clinics, all served by one hospital. Consequently, the region offers unique opportunities for community-wide implementation research.
All General Practitioners (GPs) in the region will be invited to, upon consent, select participants for the study. To reflect real-life medical practice in primary care, broad inclusion criteria have been chosen. Blood samples will be taken at the GP offices. First, the robustness of the samples regarding temperature, time and transportation to the laboratory will be studied. Second, the results of the blood samples will be compared with the results of standard diagnostic procedures at the memory outpatient clinic at the hospital. A random sample of an equal number of patients with positive and negative blood biomarker test-results will undergo blinded specialist examination, including MRIs of the brain and analysis of the cerebrospinal fluid for Alzheimer biomarkers. The diagnosis made by the specialists will then be compared to the blood-test results in order to estimate the positive and negative predictive value of such biomarkers for the diagnosis of AD in general practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The positive blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false positive blood tests (using the results from the outpatient clinic as a "gold standard" for the diagnosis)
Diagnostic Test: predictive value of a blood test
The negative blood tests results for this group will be compared with the results from the investigation at the at the memory outpatient clinic to calculate the number of false negative blood tests (using the results from the outpatient clinic as a "gold standard" for the diagnosis)
Diagnostic Test: predictive value of a blood test
Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
The positive predictive value
The positive predictive value of the blood biomarkers for diagnosing Alzheimer's disease in general practice
Time frame: 2 years
The negative predictive value
The positive predictive value of the blood biomarkers for diagnosing Alzheimer's disease in general practice
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 42 months is above that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helse Stavanger HF